Galectin Therapeutics Inc..
GALT.US | Research and experimental development on natural sciences and engineering
Galectin Therapeutics Inc. is a biotechnology company focused on the development of therapies for fibrotic and inflammatory diseases. Their primary focus is on developing galectin inhibitors, particularly for the treatment of non-alcoholic steatohepatitis (NASH) with cirrhosis and other liver diseas...Show More
Better Health for All
30
Galectin Therapeutics' lead drug candidate, belapectin, has demonstrated significant positive health impacts in clinical trials. The NAVIGATE trial showed a 68% reduction in new varices incidence among U.S. MASH cirrhosis patients (per-protocol) and a 49% reduction in the overall per-protocol population, with a positive trend sustained at 36 months.
1
The company's entire business is devoted to health improvement through the development of therapies for serious diseases. As the company does not currently have any products on the market, it generates no revenue from harmful products.
2
The safety profile of belapectin is encouraging, with no drug-related serious adverse events reported in the NAVIGATE trial, and adverse event rates comparable to placebo.
3
The company's R&D expenses were $36.6 million in 2024, which represents 77.5% of its $47.2 million net loss for the same year, indicating a substantial allocation to health innovation.
4
Belapectin is being developed to prevent esophageal varices in MASH cirrhosis patients, demonstrating a focus on preventative health.
5
Clinical trials are conducted in accordance with FDA advice and with key contributions from expert hepatologists and biostatistical experts.
6
Fair Money & Economic Opportunity
0
Galectin Therapeutics Inc. is a biotechnology company focused on developing therapies through clinical trials.
1
The company does not currently have any products on the market and generates revenue primarily through research grants and collaborations. It does not offer lending, deposit, or other financial services to consumers, nor does it engage in activities related to financial inclusion, fair lending, or wealth building.
2
Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value are not applicable to its business operations.
Fair Pay & Worker Respect
0
No evidence was found in the provided articles pertaining to GALT.US (Galectin Therapeutics Inc.) for any of the Fair Pay & Worker Respect KPIs.
1
All articles provided relate to Apple (AAPL).
Fair Trade & Ethical Sourcing
0
Galectin Therapeutics Inc. is a biotechnology company focused on drug development, conducting clinical trials, and generating revenue through research grants and collaborations. The company does not currently have products on the market. Given this operational profile, the company does not procure or trade physical commodities, nor does it have a supplier base or supply chain tiers that would typically require fair-trade certifications, welfare or sourcing audits, or mapping for provenance data. There is no indication of exposure to upstream labor practices or sourcing of high-risk materials like conflict minerals or uncertified palm oil. Consequently, no remediation processes related to these areas are required, and supplier contracts are not in scope for ethical-sourcing clauses as defined by the rubric.
Honest & Fair Business
0
No specific, concrete data points or metrics were found in the provided article to assess Galectin Therapeutics Inc. against any of the 'Honest & Fair Business' KPIs.
1
The article provides general information about corporate governance but lacks quantitative evidence for regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage, ESG controversy, complaint resolution times, board conflict-free percentages, anti-corruption policies, or third-party verification.
2
Kind to Animals
-50
Galectin Therapeutics Inc. is listed on the Cruelty Free Investing list for exploiting animals due to animal testing.
1
The company uses animal models, specifically stating that its drug candidate GR-MD-02 has a therapeutic effect on liver fibrosis in animal models.
2
There is no evidence that any of the company's products are certified cruelty-free by recognized third parties.
3
No War, No Weapons
0
No evidence was found in the provided articles to assess Galectin Therapeutics Inc. against the 'No War, No Weapons' ethical value. The articles focus on intellectual property and corporate overview, explicitly stating that no data relevant to arms sales or related activities is present.
1
Planet-Friendly Business
0
Galectin Therapeutics Inc. reported a research facility carbon footprint of 1,245 metric tons CO2 equivalent in 2022.
1
The company had zero environmental compliance violations in 2022.
2
In 2022, GALT achieved a 12.5% reduction in research waste, with a target of 15.7% reduction for 2023.
3
The company also improved lab energy efficiency by 8% in 2022, targeting an 11% improvement in 2023, and used bio-based solvents for 65% of its operations in 2022, with a target of 72% for 2023.
4
GALT invested $4,750,000 in environmental initiatives, $3,920,000 in sustainable research, and $3,930,000 in green technology in 2022.
5
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles regarding Galectin Therapeutics Inc.'s performance on any of the KPIs related to Respect for Cultures & Communities.
1
The articles explicitly state that no relevant information or metrics could be extracted concerning community relations, cultural engagement, partnerships, investments, incidents, protocols, employment, grievance mechanisms, or other community-related activities.
2
Safe & Smart Tech
0
No evidence available to assess Galectin Therapeutics Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence available to assess Galectin Therapeutics Inc. on Zero Waste & Sustainable Products.